Get all premium features to the best stock analysis tool

Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025

Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025   Vous trouverez en attaché les informations préparatoires aux Assemblées Générales Ordinaires et Extraordinaires 2025 qui auront lieu en date du 27 mars 2026. Une version PDF est disponible sur le portail de la Caisse région l'adresse suivante https://www.credit-agricole.fr/ca-tourainepoitou/particulier/informations/informations-reglementees.html#AG Attachment Informations préparatoires aux Assemblées Générales Ordinaire et Extraordinaire 2026

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS data Phase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progress Entered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the quarter and full year ended December 31, 2025, and provided a business update.

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”) a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, and Tenacia Biotechnology (Hong Kong) Co., Ltd (“Tenacia”), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including in mainland China, Hong Kong, Macau and Taiwan. RAP-219 is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being developed as part of Rapport's growing neuroscience portfolio, including in focal onset seizures (FOS) and primary generalized tonic-clonic seizures, as well as in bipolar mania.

Fantôme Rapport Launches in English — A Romance, Horror, and Mystery Adventure Aboard a Ghostly Luxury Liner

OSAKA, Japan--(BUSINESS WIRE)-- #anime--The English Ver of Fantôme Rapport launches Jan 16, 2026 (JST). A romantic horror mystery aboard a ghostly luxury liner, where bonds shape your fate.